Awaiting development: Guidance and quality standards

Showing 101 to 110 of 188

Guidance and quality standards awaiting development
Title	Type
OCU400 for treating retinitis pigmentosa in people 5 years and over [PDID6687]	Technology appraisal guidance
Odevixibat for treating biliary atresia in children following Kasai hepatoportoenterostomy [ID6627]	Technology appraisal guidance
Odronextamab for treating relapsed or refractory follicular lymphoma [TSID12236]	Technology appraisal guidance
Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912]	Technology appraisal guidance
Ondansetron for treating alcohol-use disorder [ID6341]	Technology appraisal guidance
Orforglipron for treating obstructive sleep apnoea associated with obesity or overweight [TSID12323]	Technology appraisal guidance
OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]	Highly specialised technology
Oveporexton for treating type 1 narcolepsy [ID6622]	Technology appraisal guidance
Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]	Technology appraisal guidance
Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over [TSID11865]	Technology appraisal guidance